Allovir Dividend Paid And Capex Coverage Ratio from 2010 to 2024
| ALVR Stock | USD 0.77 0.03 3.75% |
Dividend Paid And Capex Coverage Ratio | First Reported 2010-12-31 | Previous Quarter -1.6 K | Current Value -1.6 K | Quarterly Volatility 1.1 K |
Check Allovir financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Allovir's main balance sheet or income statement drivers, such as Net Interest Income of 5.5 M, Interest Income of 5.5 M or Depreciation And Amortization of 591.1 K, as well as many indicators such as Price To Sales Ratio of 9.5 K, Dividend Yield of 0.0 or PTB Ratio of 0.51. Allovir financial statements analysis is a perfect complement when working with Allovir Valuation or Volatility modules.
Allovir | Dividend Paid And Capex Coverage Ratio |
Latest Allovir's Dividend Paid And Capex Coverage Ratio Growth Pattern
Below is the plot of the Dividend Paid And Capex Coverage Ratio of Allovir over the last few years. It is Allovir's Dividend Paid And Capex Coverage Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Allovir's overall financial position and show how it may be relating to other accounts over time.
| Dividend Paid And Capex Coverage Ratio | 10 Years Trend |
|
Dividend Paid And Capex Coverage Ratio |
| Timeline |
Allovir Dividend Paid And Capex Coverage Ratio Regression Statistics
| Arithmetic Mean | (635.23) | |
| Coefficient Of Variation | (177.63) | |
| Mean Deviation | 817.90 | |
| Median | (59.45) | |
| Standard Deviation | 1,128 | |
| Sample Variance | 1.3M | |
| Range | 4K | |
| R-Value | (0.61) | |
| Mean Square Error | 852,535 | |
| R-Squared | 0.38 | |
| Significance | 0.01 | |
| Slope | (155.16) | |
| Total Sum of Squares | 17.8M |
Allovir Dividend Paid And Capex Coverage Ratio History
About Allovir Financial Statements
Allovir shareholders use historical fundamental indicators, such as Dividend Paid And Capex Coverage Ratio, to determine how well the company is positioned to perform in the future. Although Allovir investors may analyze each financial statement separately, they are all interrelated. The changes in Allovir's assets and liabilities, for example, are also reflected in the revenues and expenses on on Allovir's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Dividend Paid And Capex Coverage Ratio | -1.6 K | -1.6 K |
Pair Trading with Allovir
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allovir position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allovir will appreciate offsetting losses from the drop in the long position's value.Moving together with Allovir Stock
| 0.7 | A | Agilent Technologies Fiscal Year End 18th of November 2024 | PairCorr |
| 0.63 | BMY | Bristol Myers Squibb | PairCorr |
Moving against Allovir Stock
| 0.66 | ERNA | Eterna Therapeutics | PairCorr |
| 0.62 | PTN | Palatin Technologies | PairCorr |
| 0.59 | DYAI | Dyadic International | PairCorr |
| 0.57 | VALN | Valneva SE ADR | PairCorr |
| 0.57 | MBIO | Mustang Bio | PairCorr |
The ability to find closely correlated positions to Allovir could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allovir when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allovir - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allovir to buy it.
The correlation of Allovir is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allovir moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allovir moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allovir can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Allovir Stock Analysis
When running Allovir's price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.